Axsome Therapeutics Expects Preliminary 4Q Net Product Revenue Of $71M Vs. $66.44M Estimate; Expects FY23 Net Product Revenue Of $204M Vs. $265.95M Estimate
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics anticipates preliminary 4Q net product revenue of $71M, surpassing the $66.44M estimate. However, the company projects FY23 net product revenue to be $204M, which falls short of the $265.95M estimate.
January 04, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Axsome Therapeutics reported a higher-than-expected preliminary 4Q net product revenue of $71M, but its forecast for FY23 is below analyst expectations at $204M.
The positive 4Q revenue beat may provide a short-term stock boost. However, the lower-than-expected revenue forecast for FY23 could lead to concerns about future growth and profitability, likely resulting in a negative short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100